Tonix Pharmaceuticals, based in Chatham, New Jersey, is dedicated to repurposing drugs for central nervous system (CNS) conditions. The company is also developing a COVID-19 vaccine and engaging in biodefense projects. Their product portfolio includes TNX-SL and Tonmya™, both aimed at managing fibromyalgia. Tonix focuses on innovative solutions to address unmet medical needs in CNS disorders and infectious diseases.
Tonix Pharmaceuticals has achieved significant milestones, including highly statistically significant results in their second-phase clinical trial for TNX-SL and a positive pre-NDA CMC meeting with the FDA for Tonmya™. They have also secured a substantial contract from the U.S. Department of Defense for their broad-spectrum antiviral program. These accomplishments underscore their impact on advancing treatments for CNS conditions and infectious diseases.
